HOME >> MEDICINE >> NEWS
Results of NUVANCE phase I/II asthma trial presented

Once-a-Week Inhaled Treatment Helped Stabilize Lung Function and Was Generally Well Tolerated

MADRID, SPAIN - Results of a Phase I/II trial of NUVANCE (soluble IL-4 receptor), an investigational once-a-week inhaled asthma treatment, suggest the drug was generally well tolerated and helped stabilize lung function for up to 12 weeks following discontinuation of inhaled corticosteroids, Immunex Corporation (NASDAQ: IMNX) announced today. These results were presented today at the European Respiratory Society meeting in Madrid, Spain.

"Asthma has reached epidemic growth levels. IL-4 inhibition may change the way physicians think about asthma," said Dr. Larry Borish, associate professor in medicine, University of Virginia Medical Center and principal investigator for the NUVANCE trial. "The data presented today provide the foundation for further study of NUVANCE and IL-4 inhibition in asthma."

NUVANCE, a recombinant human version of a naturally occurring protein, represents a novel investigational approach to treating asthma. NUVANCE acts by binding to Interleukin-4 (IL-4), a protein that is present in asthmatic lungs. The binding of NUVANCE to IL-4 renders the bound IL-4 biologically inactive, which may reduce the IL-4 driven signs and symptoms of asthma.

This placebo-controlled, randomized, double-blind, Phase I/II trial was conducted in 62 adults with moderate persistent asthma, in which symptoms such as wheezing, shortness of breath and coughing occur regularly. Prior to the study, all patients were dependent on inhaled corticosteroids, daily medication intended to relieve inflammation of the airways. All patients discontinued inhaled corticosteroids when study treatment was started.

The study assessed the safety and pharmacokinetics (absorption, distribution and elimination) of inhaled NUVANCE following discontinuation of inhaled corticosteroids. Investig
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
12-Oct-1999


Page: 1 2 3 4

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... ... August 14, 2018 , ... Health & hygiene ... Report , which is the largest study of brands based on emotions. In the ... in the Top 10 for the health & hygiene industry were: Listerine, Nivea, Gillette, ...
(Date:8/11/2018)... (PRWEB) , ... August 10, 2018 , ... Dr. Siavash ... traveled to Asunción, Paraguay for a week-long international outpost trip to deliver dental care ... affiliated colleagues and support staff, Dr. Eftekhari volunteered his time to help deliver care ...
(Date:8/11/2018)... ... August 11, 2018 , ... Financial Voyages LLC CEO ... Executive of the Year-Business category in The 15th Annual International Business Awards®. , ... and organizations worldwide – public and private, for-profit and non-profit, large and small ...
(Date:8/9/2018)... , ... August 09, 2018 ... ... and outcomes by simplifying medication adherence monitoring with Smart-pill bottle and mobile ... FHIR in the App Orchard. , The DoseSmart medication management and medication ...
(Date:8/7/2018)... ... August 07, 2018 , ... Sussex Vision Center, a multi-site optometry practice ... Sussex, OD, founded the practice in Coldwater, and over the last three decades has ... to offer comprehensive eye health services for patients of all ages. , “I ...
Breaking Medicine News(10 mins):
(Date:8/7/2018)... ... August 07, 2018 , ... ... assume the role of Sanarus Technologies President, effective immediately. Mr. Stark will ... and sales experience in medical device toward finding new and innovative ways ...
(Date:8/2/2018)... ... August 02, 2018 , ... The American Heart Association/American Stroke ... Wednesday, July 11, 2018, recognizing the hospital’s commitment to compliance with quality measures ... , Get With The Guidelines®-Stroke Gold Plus Quality Achievement Award ...
(Date:8/2/2018)... ... August 02, 2018 , ... Clay and Associates DDS, ... 1st. Dr. Wallingford will join Dr. John Clay and Dr. Shaun O’Neill as ... a positive experience for all of their patients' dental hygiene, encapsulates the core values ...
Breaking Medicine Technology:
Cached News: